Cancer prevention and health management are moving toward more convenient and precise approaches. In recent years, liquid biopsy technologies that analyze molecular signals from blood samples have advanced rapidly, creating new opportunities for disease risk assessment and precision healthcare.

At BIO Asia–Taiwan 2026, EG BioMed will present its featured theme, “Blood-Based Early Cancer Detection,” highlighting the potential applications of DNA methylation biomarkers in precision health and disease risk assessment.

Key exhibition highlights include:

• Applications of liquid biopsy-based molecular analysis
• Multi-cancer DNA methylation biomarker platforms
• Research directions related to risk assessment for pancreatic, liver, colorectal, and other digestive system diseases
• Non-invasive, convenient, and highly accepted testing approaches

DNA methylation has emerged as one of the most important areas of research in precision medicine and molecular diagnostics. By analyzing methylation patterns in blood-derived DNA, researchers can gain insights into biological changes associated with health and disease, supporting the development of more personalized healthcare strategies.

Compared with traditional diagnostic procedures, blood-based approaches offer greater convenience, minimal invasiveness, and higher patient acceptance. These advantages provide significant potential for health screening, disease risk assessment, and long-term health monitoring.

EG BioMed continues to invest in DNA methylation biomarker research and international testing services. Supported by collaboration with CLIA- and CAP-certified laboratory resources in the United States, the company is committed to advancing precision medicine and global diagnostic partnerships.

The exhibition is expected to attract hospitals, health screening centers, oncology specialists, international distributors, and biotechnology partners interested in exploring future opportunities in liquid biopsy and DNA methylation-based precision healthcare.